JP2017025056A - Piperine-containing oral composition - Google Patents
Piperine-containing oral composition Download PDFInfo
- Publication number
- JP2017025056A JP2017025056A JP2016119969A JP2016119969A JP2017025056A JP 2017025056 A JP2017025056 A JP 2017025056A JP 2016119969 A JP2016119969 A JP 2016119969A JP 2016119969 A JP2016119969 A JP 2016119969A JP 2017025056 A JP2017025056 A JP 2017025056A
- Authority
- JP
- Japan
- Prior art keywords
- piperine
- blood pressure
- composition
- food
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 title claims abstract description 34
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 title claims abstract description 34
- 229940075559 piperine Drugs 0.000 title claims abstract description 34
- 235000019100 piperine Nutrition 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 230000036772 blood pressure Effects 0.000 claims description 12
- 241000758706 Piperaceae Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 20
- 235000013305 food Nutrition 0.000 description 18
- 239000000284 extract Substances 0.000 description 17
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 230000002354 daily effect Effects 0.000 description 8
- 230000035487 diastolic blood pressure Effects 0.000 description 7
- 230000035488 systolic blood pressure Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 241001504519 Papio ursinus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000004531 blood pressure lowering effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 235000010523 Cicer arietinum Nutrition 0.000 description 2
- 244000045195 Cicer arietinum Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 235000020333 oolong tea Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- -1 rice Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 240000003173 Drymaria cordata Species 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、血圧を低下させることが可能な、ピペリン含有経口組成物に関する。 The present invention relates to a piperine-containing oral composition capable of lowering blood pressure.
高血圧は別名「サイレント・キラー」と呼ばれ、自覚症状無く進行するケースが多く、動脈硬化症や心臓病、脳卒中等、様々な循環器疾患を引き起こす原因となる。脳血管疾患や心疾患を含む循環器系疾患は日本における主要死因の一つであり（非特許文献１）、これらの疾患は患者自身の身体的及び金銭的負担が大きいことに加え、介護者等の周囲の人々や国民医療費の増加など社会的な負担も大きいことから、毎日摂取しても安全な血圧低下剤は、高血圧の予防、治療の観点からも強く求められている。これまで天然物由来の血圧低下剤としてクロロゲン酸（非特許文献２）、燕龍茶フラボノイド（非特許文献３）などが知られている。しかし、クロロゲン酸の場合、１日２９９ｍｇもの多量を摂取しても収縮期血圧及び拡張期血圧においてプラセボに対して有意差が認められるまで１０週間を要する。また、燕龍茶フラボノイドの場合、１日３０ｍｇもの多量を摂取しても収縮期血圧及び拡張期血圧においてプラセボに対して有意差が認められるまで８週間を要する。したがって、より少量でかつ短期間で効果を発現する天然物由来の血圧低下剤が求められている。 Hypertension, also known as “silent killer”, often progresses without subjective symptoms and causes various cardiovascular diseases such as arteriosclerosis, heart disease, and stroke. Cardiovascular diseases including cerebrovascular diseases and heart diseases are one of the major causes of death in Japan (Non-patent Document 1), and these diseases have a large physical and monetary burden on patients themselves, as well as caregivers. Therefore, a blood pressure-lowering agent that is safe even if taken daily is strongly demanded from the viewpoint of prevention and treatment of hypertension. So far, chlorogenic acid (Non-patent document 2), Oolong tea flavonoid (Non-patent document 3) and the like are known as blood pressure lowering agents derived from natural products. However, in the case of chlorogenic acid, it takes 10 weeks until a significant difference is observed with respect to placebo in systolic blood pressure and diastolic blood pressure even if a large amount of 299 mg is ingested daily. In the case of oolong tea flavonoids, it takes 8 weeks until a significant difference is observed with respect to placebo in systolic blood pressure and diastolic blood pressure even if a large amount of 30 mg per day is ingested. Therefore, there is a demand for a natural product-derived blood pressure-lowering agent that produces an effect in a smaller amount and in a short period of time.
ヒハツ（英名：Ｌｏｎｇ ｐｅｐｐｅｒ）は東南アジアに分布するコショウ科の植物である。ヒハツ抽出物には様々な作用が知られているが、例えば特許文献１ではヒハツ抽出物がアンジオテンシンにより誘導される血圧上昇を抑制することが示されている。しかしながら、一般的に植物やその抽出物はその含有成分が必ずしも均一ではないことから、確実に血圧低下作用を有する組成物を、安定的に提供することは困難である。 Hibatsu (English: Long pepper) is a pepper family plant distributed in Southeast Asia. Various actions are known for the extract of Hibatsu. For example, Patent Document 1 shows that the extract of Hihatsu suppresses an increase in blood pressure induced by angiotensin. However, in general, since the components contained in plants and extracts thereof are not necessarily uniform, it is difficult to stably provide a composition having a blood pressure lowering effect.
本発明の目的は、毎日摂取しても安全で、かつ確実に血圧低下作用を示す組成物を安定的に提供することである。 An object of the present invention is to stably provide a composition that is safe even when taken daily and exhibits a blood pressure lowering action with certainty.
本発明者らは、課題を解決するために種々検討した結果、ヒハツ抽出物に含まれるピペリンが血圧を低下させることを見出し、本発明を完成した。 As a result of various investigations to solve the problems, the present inventors have found that piperine contained in the extract of Hihatsu reduces blood pressure, and completed the present invention.
すなわち本発明は、
（１）一日の摂取量当たり、ピペリンを３０μｇ以上含有することを特徴とする経口組成物、
（２）ピペリンがコショウ科植物に由来する、請求項１に記載の経口組成物、
（３）一日の摂取量当たり、ピペリンを有効成分として３０μｇ以上含有することを特徴とする、血圧低下用経口組成物、又は
（４）飲食品組成物である（１）〜（３）のいずれかに記載の組成物。
である。
That is, the present invention
(1) An oral composition containing 30 μg or more of piperine per daily intake,
(2) The oral composition according to claim 1, wherein piperine is derived from a pepper family plant,
(3) An oral composition for lowering blood pressure, or (4) a food or beverage composition, characterized by containing 30 μg or more of piperine as an active ingredient per daily intake. A composition according to any one of the above.
It is.
本発明のピペリンを３０μｇ以上含有するヒハツ抽出物は、血圧を低下させることが示された。 It has been shown that a chickpea extract containing 30 μg or more of piperine of the present invention lowers blood pressure.
ピペリンはアルカロイドの一種であり、下記構造式で表される化合物である。 Piperine is a kind of alkaloid and is a compound represented by the following structural formula.
ピペリンは植物原料又は植物原料から抽出又は精製したものであってもよいし、人工的に合成されたものであってもよいが、安全性の観点から植物原料又は植物原料から抽出又は精製したものを用いることが好ましい。ピペリンはコショウ科植物に多く含まれることから、前記植物原料としては、コショウ科植物を用いることが出来るが、コショウ又はヒハツが好ましく、特にヒハツが好ましい。 Piperine may be extracted or purified from plant materials or plant materials, or may be artificially synthesized, but is extracted or purified from plant materials or plant materials from the viewpoint of safety. Is preferably used. Since piperine is contained in a large amount in pepper family plants, a pepper family plant can be used as the plant raw material. Pepper or baboon is preferable, and baboon is particularly preferable.
本発明において、ヒハツ抽出物とは、ヒハツを溶媒で抽出したものである。溶媒としては、水、メタノール、エタノール等のアルコール類、プロピレングリコール、１，３−ブチレングリコール等の多価アルコール類、アセトン等のケトン類等の有機溶媒を、単独又は２種以上組み合わせて使用することができる。抽出物は、上記抽出物をそのまま使用することも、乾燥エキス、流エキス、チンキ等の一般的な形態のものを用いることもできる。 In the present invention, the “hihatsu extract” is obtained by extracting hihatsu with a solvent. As the solvent, water, alcohols such as methanol and ethanol, polyhydric alcohols such as propylene glycol and 1,3-butylene glycol, and organic solvents such as ketones such as acetone are used alone or in combination of two or more. be able to. As the extract, the above-mentioned extract can be used as it is, or those in a general form such as a dry extract, a stream extract, tincture and the like can be used.
本発明の剤形は特に限定されず、錠剤、カプセル剤、細粒剤、微粒剤、液剤、チュアブル剤、トローチなどの形態で摂取することが可能であるが、毎日続けて摂取しやすい剤形である茶風味の液剤や茶、茶抽出物又は米等を添加した製剤（摂取時に液体を添加する）が好ましい。本発明の組成物を医薬組成物として用いる場合には、内服用固形剤や内服用液剤などの経口用製剤として提供することが好ましい。本発明の組成物を飲食品組成物として用いる場合、当該飲食品組成物は、例えば、健康食品、機能性表示食品、特定保健用食品、栄養補助食品、病者用食品、あるいは食品添加物であり得る。飲食品組成物の具体例としては、ドリンク類、スープ類、乳飲料、清涼飲料水、茶飲料、アルコール飲料、ゼリー状飲料、機能性飲料等の液状食品；食用油、ドレッシング、マヨネーズ、マーガリンなどの油分を含む製品；飯類、麺類、パン類等の炭水化物含有食品；ハム、ソーセージ等の畜産加工食品；かまぼこ、干物、塩辛等の水産加工食品；漬物等の野菜加工食品；ゼリー、ヨーグルト等の半固形状食品；みそ、発酵飲料等の発酵食品；洋菓子類、和菓子類、キャンディー類、ガム類、グミ、冷菓、氷菓等の各種菓子類；カレー、あんかけ、中華スープ等のレトルト製品；インスタントスープ、インスタントみそ汁等のインスタント食品や電子レンジ対応食品等が挙げられる。さらには、粉末、穎粒、錠剤、カプセル剤、液状、ペースト状またはゼリー状に調製された健康飲食品も挙げられる。本発明における飲食品組成物の製造は、当該技術分野に公知の製造技術により実施することができる。 The dosage form of the present invention is not particularly limited and can be ingested in the form of tablets, capsules, fine granules, fine granules, liquids, chewables, troches, etc., but is easy to ingest continuously every day. A tea-flavored liquid or a preparation to which tea, tea extract, rice or the like is added (a liquid is added when ingested) is preferred. When the composition of the present invention is used as a pharmaceutical composition, it is preferably provided as an oral preparation such as a solid preparation for internal use or a liquid for internal use. When the composition of the present invention is used as a food / beverage product composition, the food / beverage product composition is, for example, a health food, a functional indication food, a food for specified health use, a nutritional supplement, a food for a sick person, or a food additive. possible. Specific examples of the food and beverage composition include liquid foods such as drinks, soups, milk beverages, soft drinks, tea beverages, alcoholic beverages, jelly-like beverages, functional beverages; edible oils, dressings, mayonnaise, margarines, etc. Products containing carbohydrates; Foods containing carbohydrates such as rice, noodles and bread; Livestock processed foods such as ham and sausage; Fish processed foods such as kamaboko, dried fish and salted fish; Vegetable processed foods such as pickles; Jelly, yogurt, etc. Semi-solid foods; fermented foods such as miso and fermented beverages; various confectioneries such as Western confectionery, Japanese confectionery, candy, gums, gummi, frozen confectionery, ice confectionery; retort products such as curry, ankake, Chinese soup; instant Examples include instant foods such as soup and instant miso soup, and foods compatible with microwave ovens. Furthermore, health foods and drinks prepared in the form of powder, granules, tablets, capsules, liquid, paste or jelly are also included. Manufacture of the food-drinks composition in this invention can be implemented with a manufacturing technique well-known in the said technical field.
また、発明の効果を損なわない質的および量的範囲で、必要に応じて他の公知の添加剤として、生薬、天然物、賦形剤、ｐＨ調整剤、清涼化剤、懸濁化剤、粘稠剤、溶解補助剤、崩壊剤、結合剤、滑沢剤、抗酸化剤、コーティング剤、着色剤、矯味剤、界面活性剤、可塑剤、香料などを混合することができる。 In addition, as necessary, other known additives in a qualitative and quantitative range that do not impair the effects of the invention include crude drugs, natural products, excipients, pH adjusters, cooling agents, suspending agents, A thickener, a solubilizer, a disintegrant, a binder, a lubricant, an antioxidant, a coating agent, a coloring agent, a corrigent, a surfactant, a plasticizer, a fragrance, and the like can be mixed.
本発明の経口組成物には、一日の摂取量当たり３０μｇ以上のピペリンを含有する。摂取開始後のより早い時期に十分な血圧低下作用を発揮させるという点から、一日の摂取量当たり９０μｇ以上のピペリンを含有することがさらに好ましい。ピペリンの含有量は高速液体クロマトグラフィー（ＨＰＬＣ）により測定することが出来るが、測定方法としてＨＰＬＣに限定するものではない。 The oral composition of the present invention contains 30 μg or more of piperine per daily intake. It is more preferable to contain 90 μg or more of piperine per daily intake from the viewpoint of exerting a sufficient blood pressure lowering effect at an earlier time after the start of intake. The piperine content can be measured by high performance liquid chromatography (HPLC), but the measurement method is not limited to HPLC.
以下に、本発明をさらに具体的に説明するが、本発明の範囲はこれに限定されるものではない。
１．試験品
試験に用いるヒハツ抽出物は、乾燥したヒハツを熱水抽出し、デキストリンを添加した後、乾燥させることにより調製した。調製したヒハツ抽出物、矯味剤（緑茶、緑茶抽出物、米）及び賦形剤を使用して、プラセボ品（１包中にヒハツ抽出物由来のピペリンを含有しない粉末）、３０μｇピペリン含有品（１包中にヒハツ抽出物由来のピペリンとして３０μｇ含有する粉末）、６０μｇピペリン含有品（１包中にヒハツ抽出物由来のピペリンとして６０μｇ含有する粉末）及び９０μｇピペリン含有品（１包中にヒハツ抽出物由来のピペリンとして９０μｇ含有する粉末）を１包当たり３ｇとなるように作製した。なお各試験品はそれぞれ外観から判別ができないようにアルミスティックへ充填した。また試験品に含まれるピペリンはＨＰＬＣにより測定した。
２．被験者
対象は、高血圧治療ガイドライン２００９にて分類されている正常高値血圧者又はＩ度高血圧者のうち、医師の管理下での治療が必須ではないと考えられる者とした。
プラセボ群（プラセボ品を摂取した群）、３０μｇ群（３０μｇピペリン含有品を摂取した群）、６０μｇ群（６０μｇピペリン含有品を摂取した群）及び９０μｇ群（９０μｇピペリン含有品を摂取した群）の４群にて実施した。選択・除外基準に従い被験者を１２０名（男性９０名、女性３０名）選定した。なお、本試験では血圧に影響を与える可能性のある薬剤の使用を禁止した。
３．試験方法
本試験は、ランダム化、二重盲検、プラセボ対照、並行群間比較にて実施した。 摂取期間は８週間とし、被験者は、摂取開始時から８週後来院時まで毎日試験品１包を１００ｍＬのお湯又は水に溶かし１日１回摂取した。
４．評価方法
本試験の有効性評価項目は、収縮期血圧（坐位）及び拡張期血圧（坐位）とし、各評価時期における摂取開始時からの変化量を評価指標とした。なお、摂取開始時、１週後、２週後、４週後、６週後、８週後に血圧測定を実施した。
５．試験結果
収縮期血圧の推移を図１に、拡張期血圧の推移を図２に示した。３０μｇ群ではプラセボ群に対し、摂取４週後の拡張期血圧において有意な低下を認め、また６０μｇ群ではプラセボ群に対し、摂取２週後の収縮期血圧において有意な低下を認めた。９０μｇ群ではプラセボ群に対し、収縮期血圧及び拡張期血圧共に、摂取２週以降の全ての評価時期において有意な低下を認めた。以上の結果から、ピペリンが血圧低下作用を示すためには、一日の摂取量として３０μｇ以上、より好ましくは９０μｇ以上必要であることが明らかとなった。
Hereinafter, the present invention will be described more specifically, but the scope of the present invention is not limited thereto.
1. Test product The extract of the chickpea used in the test was prepared by extracting the dried chickweed with hot water, adding dextrin, and drying the extract. Placebo product (powder not containing piperine derived from Hihatsu extract in one package), 30 μg piperine-containing product using the prepared Hihatsu extract, flavoring agent (green tea, green tea extract, rice) and excipients ( 1 sachet containing 30 μg of piperine derived from the extract of cherries, 60 μg piperine-containing product (powder containing 60 μg of piperine derived from baboon extract in one sachet) (Powder containing 90 μg of piperine derived from the product) was prepared so as to be 3 g per packet. Each test product was filled in an aluminum stick so that it could not be distinguished from the appearance. Piperine contained in the test product was measured by HPLC.
2. Subjects The subjects were normal high blood pressure persons or I-degree hypertensive persons classified according to the hypertension treatment guideline 2009, and those who are considered not to require treatment under the control of a doctor.
Placebo group (group that ingested placebo product), 30 μg group (group that ingested 30 μg piperine-containing product), 60 μg group (group that ingested 60 μg piperine-containing product), and 90 μg group (group that ingested 90 μg piperine-containing product) Conducted in 4 groups. 120 subjects (90 men and 30 women) were selected according to the selection / exclusion criteria. In this study, the use of drugs that may affect blood pressure was prohibited.
3. Test Method The study was conducted in a randomized, double-blind, placebo-controlled, parallel group comparison. The ingestion period was 8 weeks, and the test subjects were ingested once a day by dissolving 1 test sample in 100 mL of hot water or water every day from the start of ingestion until 8 weeks later.
4). Evaluation Method The efficacy evaluation items in this study were systolic blood pressure (sitting position) and diastolic blood pressure (sitting position), and the amount of change from the start of intake in each evaluation period was used as an evaluation index. At the start of intake, blood pressure was measured after 1 week, 2 weeks, 4 weeks, 6 weeks, and 8 weeks.
5). Test Results The changes in systolic blood pressure are shown in FIG. 1, and the changes in diastolic blood pressure are shown in FIG. In the 30 μg group, there was a significant decrease in diastolic blood pressure 4 weeks after ingestion compared to the placebo group, and in the 60 μg group, there was a significant decrease in systolic blood pressure 2 weeks after ingestion compared to the placebo group. In the 90 μg group, both the systolic blood pressure and the diastolic blood pressure significantly decreased at all evaluation periods after 2 weeks of intake, compared to the placebo group. From the above results, it has been clarified that in order for piperine to exhibit a blood pressure lowering effect, the daily intake is required to be 30 μg or more, more preferably 90 μg or more.
一方、試験期間中に副作用の発現はいずれの群でも認められなかった。 On the other hand, no side effects were observed in any group during the study period.
本発明の組成物又は血圧低下用組成物は、医薬品、医薬部外品、「血圧が気になる方に」などの表示を付した特定保健用食品（健康増進法第２６条第１項の許可又は第２９条第１項の承認を受け、食生活において特定の保健の目的で摂取する者に対し、その摂取により当該保健の目的が期待できる旨の表示をする食品）さらには「血圧を改善する機能があります」などの表示を付した機能性表示食品（機能性表示食品制度などに基づき、事業者が食品の安全性と機能性に関する科学的根拠などの必要な事項を、販売前に消費者庁長官に届け出れば、機能性を表示することができる食品）など、規制当局が保健の目的又は機能性などの表示を認めている食品として利用することが可能である。 The composition of the present invention or the composition for lowering blood pressure is a pharmaceutical product, a quasi-drug, a food for specified health use with a label such as “For those who are concerned about blood pressure” (Article 26, Paragraph 1 of the Health Promotion Act). Foods that have been approved or approved by Article 29, paragraph 1 and that are intended to be taken for specific health purposes in the diet and that the purpose of the health can be expected by their consumption) Functional labeling food with a label such as `` There is a function to improve '' (based on the functional labeling food system etc., the business operator will carry out necessary matters such as scientific grounds on food safety and functionality before sales If it is notified to the Commissioner of the Consumer Affairs Agency, it can be used as food approved by the regulatory authorities, such as foods that can display functionality).
Claims (4)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015147383 | 2015-07-27 | ||
| JP2015147383 | 2015-07-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017025056A true JP2017025056A (en) | 2017-02-02 |
| JP6862688B2 JP6862688B2 (en) | 2021-04-21 |
Family
ID=57945364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016119969A Active JP6862688B2 (en) | 2015-07-27 | 2016-06-16 | Oral composition containing piperine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6862688B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114586976A (en) * | 2021-11-12 | 2022-06-07 | 海南省农业科学院农产品加工设计研究所 | Composite piperine concentrated powder and preparation method thereof |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002080356A (en) * | 2000-09-05 | 2002-03-19 | Kao Corp | Preventing and treating agent for hypertension |
| JP2005112846A (en) * | 2003-09-17 | 2005-04-28 | Lequio Pharma Co Ltd | Turmeric-containing composition |
| JP2005162745A (en) * | 2003-11-13 | 2005-06-23 | Taisho Pharmaceut Co Ltd | Ameliorating agent for hypertension |
| JP2005350422A (en) * | 2004-06-14 | 2005-12-22 | Sanei Seiyaku Kk | Active oxygen scavenger |
| JP2007274929A (en) * | 2006-04-04 | 2007-10-25 | Calpis Co Ltd | Hot beverage having warm feeling-retaining effect |
| JP2009149585A (en) * | 2007-12-21 | 2009-07-09 | Maruzen Pharmaceut Co Ltd | Skin irritation-relieving agent and skin care preparation for external use |
| JP2009173639A (en) * | 2007-12-27 | 2009-08-06 | Taisho Pharmaceutical Co Ltd | Stomach-adaptive relaxation ameliorating agent |
| JP2010110283A (en) * | 2008-11-07 | 2010-05-20 | Kobayashi Pharmaceut Co Ltd | Food/drink composition containing piper longum extract, and method for ameliorating taste of the composition |
| WO2012141018A1 (en) * | 2011-04-15 | 2012-10-18 | ライオン株式会社 | Composition, glucose metabolism-improving agent, and method for improving glucose metabolism |
| WO2014010656A1 (en) * | 2012-07-11 | 2014-01-16 | 興和株式会社 | Superior blood alcohol concentration reduction accelerating agent |
| JP2015010068A (en) * | 2013-06-28 | 2015-01-19 | 小林製薬株式会社 | Serenoa repens extracts-containing formulation |
-
2016
- 2016-06-16 JP JP2016119969A patent/JP6862688B2/en active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002080356A (en) * | 2000-09-05 | 2002-03-19 | Kao Corp | Preventing and treating agent for hypertension |
| JP2005112846A (en) * | 2003-09-17 | 2005-04-28 | Lequio Pharma Co Ltd | Turmeric-containing composition |
| JP2005162745A (en) * | 2003-11-13 | 2005-06-23 | Taisho Pharmaceut Co Ltd | Ameliorating agent for hypertension |
| JP2005350422A (en) * | 2004-06-14 | 2005-12-22 | Sanei Seiyaku Kk | Active oxygen scavenger |
| JP2007274929A (en) * | 2006-04-04 | 2007-10-25 | Calpis Co Ltd | Hot beverage having warm feeling-retaining effect |
| JP2009149585A (en) * | 2007-12-21 | 2009-07-09 | Maruzen Pharmaceut Co Ltd | Skin irritation-relieving agent and skin care preparation for external use |
| JP2009173639A (en) * | 2007-12-27 | 2009-08-06 | Taisho Pharmaceutical Co Ltd | Stomach-adaptive relaxation ameliorating agent |
| JP2010110283A (en) * | 2008-11-07 | 2010-05-20 | Kobayashi Pharmaceut Co Ltd | Food/drink composition containing piper longum extract, and method for ameliorating taste of the composition |
| WO2012141018A1 (en) * | 2011-04-15 | 2012-10-18 | ライオン株式会社 | Composition, glucose metabolism-improving agent, and method for improving glucose metabolism |
| WO2014010656A1 (en) * | 2012-07-11 | 2014-01-16 | 興和株式会社 | Superior blood alcohol concentration reduction accelerating agent |
| JP2015010068A (en) * | 2013-06-28 | 2015-01-19 | 小林製薬株式会社 | Serenoa repens extracts-containing formulation |
Non-Patent Citations (1)
| Title |
|---|
| INT. J. RES. PHARM. SCI., vol. Vol.1, Issue 3, JPN7020001230, 2010, pages 300 - 307, ISSN: 0004395019 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114586976A (en) * | 2021-11-12 | 2022-06-07 | 海南省农业科学院农产品加工设计研究所 | Composite piperine concentrated powder and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6862688B2 (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hofer et al. | Caloric restriction mimetics in nutrition and clinical trials | |
| JP2009161459A (en) | Endurance-improving agent | |
| JP5888574B1 (en) | Blood flow improver | |
| JP6773361B2 (en) | Mood condition improver | |
| JP2008214191A (en) | Agent for suppressing accumulation of lipid in liver | |
| JP6584270B2 (en) | Blood flow improving composition | |
| Okano et al. | Chemoprevention against hepatocellular carcinoma | |
| JP6862688B2 (en) | Oral composition containing piperine | |
| JP3860133B2 (en) | Diet food | |
| JP2007254427A (en) | Antioxidant and its use | |
| JP2017178805A (en) | Lps production inhibiting agent, and food composition for inhibiting lps production | |
| JP2009114158A (en) | Blood sugar level rising inhibitor | |
| JP2011162504A (en) | Atp production promoter and use thereof | |
| JP2012131760A (en) | Fatty acid absorption inhibitor | |
| CN114007604A (en) | Hepatic fibrosis inhibitor and brown fat cell activator containing taxifolin | |
| JP6981641B2 (en) | PDE5 activity inhibitor | |
| JP5608877B2 (en) | Swelling preventive and oral composition | |
| JP2019180412A (en) | Oral composition | |
| KR101533910B1 (en) | Composition for preventing and improving hyperlipidemia comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube | |
| JP2019176828A (en) | Oral composition | |
| JP2005053786A (en) | Food and drink comprising extract derived from citrus pericarp and having inhibitory action on blood pressure rise | |
| JPWO2005056031A1 (en) | Lipase inhibitor | |
| JP2011132147A (en) | Neutral fat absorption inhibitor comprising concentrated red wine essence as effective ingredient | |
| JP2008156292A (en) | Peripheral bloodstream-improving agent and food composition having peripheral bloodstream-improving activity | |
| JP2011121919A (en) | Lipid absorption inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190606 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200417 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200519 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201228 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210302 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210315 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6862688 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |